Luminescent heparin-functionalized carbon dots with potential applications in nanoparticle-protein interactions and cell imaging Authors: Ipsita Kumar Sen, Maidul Hossain, Debesh Chandra Bhattacharya, Anoop Kumar, Ahmet Kati, Amiya Kumar Panda, M Deniz Yilmaz, Amit Kumar Mandal Published: 2026 ABSTRACT AbstractIn this study, we report the synthesis and comprehensive characterization of heparin-capped carbon dots (Hep-C-dots) prepared using D-glucose as a carbon precursor and heparin, a negatively charged polysaccharide belonging to the glycosaminoglycan family, as a capping and stabilizing agent. The obtained Hep-C-dots exhibited a uniform nanoscale size distribution with an average diameter of 2.5 ± 0.5 nm and a high negative surface charge (− 36.8 mV). Full characterization of as-synthesized Hep-C-dots has been done by several state-of-the-art analytical techniques, such as transmission electron microscopy (TEM), X-ray diffraction (XRD), UV–visible spectroscopy, Fourier-transform infrared (FTIR) spectroscopy, and zeta potential analysis. The interactions between Hep-C-dots and key human proteins, namely human methemoglobin (HB) and human serum albumin (HSA), were investigated via fluorescence spectroscopy, demonstrating significant binding affinities with Ksv values of 2.61 ± 0.5 × 107 M− 1 for HSA and 1.83 ± 0.4 × 107 M− 1 for HB. Cytotoxicity assays performed on A549 lung cancer cells revealed that Hep-C-dots exhibit slightly higher toxicity compared to bare carbon dots (C-dots), with IC50 values of 176.21 µg/mL and 200.4 µg/mL, respectively. Moreover, hemolysis assessment using bovine red blood cells (RBCs) showed that Hep-C-dots induce negligible hemolysis (0.002% at 200 µg/mL), confirming their excellent hemocompatibility. These findings suggest that Hep-C-dots hold promise as biocompatible nanomaterials for biomedical applications.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54338-x.Keywords: Heparin, carbon dots, protein–nanoparticle interaction, cytotoxicity assay, hemocompatibility, luminescent, nanomaterialsSubject terms: Biochemistry, Biological techniques, Biotechnology, Chemistry, Materials science, Nanoscience and technology Introduction Quantum dots (QDs) are unique imaging agents owing to the quantum size effect, which allows their fluorescence emission to be tuned by particle size.1 However, traditional QDs often contain heavy metals, restricting their biomedical applications due to toxicity concerns. This limitation has driven the search for new fluorescent nanomaterials with lower toxicity and improved biocompatibility. Carbon dots (C-dots) have emerged as promising alternatives because of their non-toxic nature, excellent biocompatibility, and reliable optical properties.2,3 For instance, C-dots exhibit low cytotoxicity in HeLa cells after 24 h, while much lower concentrations suffice for effective cell imaging.4 Furthermore, C-dots smaller than 6 nm are rapidly excreted via urine anddisplay minimal liver retention.5. The global rise of non-communicable diseases such as cancer underscores the urgent need for innovative and targeted therapeutic strategies. Nanobiotechnology offers significant potential for developing anticancer agents capable of selectively targeting cancer cells while sparing healthy tissues. The distinct physicochemical and electronic properties of nanomaterials at the nanoscale enable enhanced biomedical functionalities compared to bulk counterparts.6–10 The efficacy of these biomedical functionalities is largely dictated by the bio-interfacial dynamics between nanomaterials and biological environments, particularly regarding nanoparticle-protein interactions. The spontaneous interaction between nanomaterials and biological proteins results in the development of a protein corona, which essentially redefines the nanoparticle’s biological identity and dictates its cellular uptake and biocompatibility.10 Carbon-based nanomaterials, including C-dots, have garnered attention as promising nanomedicines due to their low toxicity and selective cellular interactions.11–14. C-dots can be synthesized via top-down methods such as electrochemical oxidation, laser ablation, and arc discharge,15,16 as well as bottom-up approaches including thermal treatment and microwave-assisted synthesis.17,18 More recently, environmentally friendly green synthesis methods using renewable biomass—such as plant leaves, flowers, roots, kernels, bark, stalks, and peels—have been developed to reduce production costs and enhance sustainability.19–25 Biocompatible and biodegradable carbohydrates like chitosan, alginate, cellulose, and other saccharides have also been successfully utilized to functionalize C-dots due to their eco-friendly nature, abundance, high biocompatibility, and availability in large quantities with affordable prices.26–31 Even though various studies were reported on the synthesis, characterization and biomedical applications of carbohydrate polymer- functionalized carbon dots, there is no report on the biological activity of heparin-stabilized carbon dots (Hep-C-dots) as biocompatible luminescent nanomaterials in biomedical applications. In the present study, we report luminescent heparin functionalized carbon dots with potential applications in nanoparticle-protein interactions and cell imaging. Heparin is composed of repeating disaccharide units of 2-O-sulfated iduronic acid and 6-O-sulfated, N-sulphated glucosamine, conferring high water solubility to the heparin-capped C-dots (Hep-C-dots). The novelty of this study lies in the functionalization of simple carbon dots with heparin to develop an advanced nano-biomaterial. These heparin-functionalized carbon dots (Hep-C-dots) exhibit strong photoluminescence while maintaining safe interactions with key blood proteins, namely hemoglobin (HB) and human serum albumin (HSA), without inducing structural damage. Notably, Hep-C-dots show enhanced anticancer activity against A549 lung cancer cells compared to naked carbon dots, indicating that heparin incorporation improves surface-driven cellular interactions. Furthermore, their clinical applicability has been validated through systematic evaluation of protein-binding affinity, selective cytotoxicity, and hemocompatibility, positioning Hep-C-dots as a promising multifunctional platform for advanced biomedical applications. Experimental section Materials Unless otherwise noted, reagents and solvents were reagent grade and used without further purification. D-glucose, sulfuric acid (concentrated, ~ 98%), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2 H-tetrazolium bromide (MTT), and fetal calf serum (FCS) were purchased from Sigma-Aldrich. Heparin sodium salt (ex. Bovine intestinal mucosa, 150 IU/mg, molecular weight approx. 15–19 kDa, sulfated ash 28–41%) was obtained from Sisco Research Laboratories Pvt. Ltd., India. Purified water (resistivity > 18 MΩ cm) from Milli-Q system was used in all experiments. Synthesis of carbon dots Bare C-dots were prepared via dehydration of D-glucose. In brief, 250 mg of D-glucose was suspended in 10 mL of concentrated sulfuric acid and stirred continuously until the solution turned faint yellow. After 20 min of acid treatment, the mixture was heated at 150 °C for 2 min to complete the dehydration process. During heating, the solution color changed gradually from faint yellow to brownish black, indicating C-dot formation. The reaction mixture was then cooled to room temperature and added dropwise into 100 mL of ice-cold ultrapure water under vigorous stirring, yielding a black precipitate. The large precipitates were removed by centrifugation at 8,000 rpm for 30 min. The supernatant was centrifuged at 14,000 rpm for 30 min to collect C-dots, followed by multiple washes with distilled water to remove ionic impurities. The purified C-dots were subsequently stabilized by suspending in 50 mL of 0.5% (w/v) heparin solution. The mixture was stirred for 1 h at room temperature and centrifuged at 14,000 rpm for 30 min to remove excess heparin. Finally, precipitated heparin-capped carbon dots (Hep-C-dots) were freeze-dried for further characterization and studies. Characterization of carbon dots The heparin-capped carbon dots (Hep-C-dots) was characterized by UV−visible spectroscopy, transmission electron microscopy (TEM), X-Ray Diffraction (XRD) pattern analysis, Infrared spectroscopy and zeta potential analyzer. The size and morphological characteristics of heparin-capped carbon dots were analyzed using electron microscopy (TEM) (JEOL model JEM 2100 instrument operated at an accelerating voltage at 200 kV). For TEM analysis, 100 µL of the synthesized Hep-C-dots were dispersed in 5 mL distilled water and subjected to sonication (100 W, 30 kHz) for 5 min prior to drop casting over carbon-coated copper grid. A droplet of solutions of Hep-C-dots was spread onto a carbon coated copper grid (300 meshes) and dried under vacuum. The XRD pattern analysis of Hep-C-dots was carried out with a Rigaku Ultima-IV X-ray diffractometer using Cu Kα (λ = 0.15406 nm) radiation in the range of 20° ≤ 2θ ≤ 80° at 40 kV. The FT-IR spectrum of Hep-C-dots was performed using a Bruker IFS 66/S spectrometer in the wavelength range of 4000 –400 cm− 1 at room temperature. The zeta potential of C-dots and Hep-C-dots was determined at 25 °C by dynamic light scattering analysis using Zetasizer Nano ZS90 (Malvern, U.K.). The suspensions were sonicated for 3 min prior to use to minimize aggregation of nanoparticles and zeta potential measurements were performed for two independent samples. UV–vis absorption and steady-state fluorescence measurements were done by using Shimadzu UV3600i plus UV–vis–NIR and Agilent Cary Eclipse spectrophotometers, respectively. The fluorescence quantum yields were calculated by a relative method with quinine sulfate as the reference standard (ΦF = 0.54 in 0.1 M H2SO4). Protein binding experiments Fluorescence and circular dichroism spectroscopy were employed to investigate the binding interactions of Hep-C-dots with model proteins—human methemoglobin (HB) and human serum albumin (HSA). Both HB and HSA (≥ 98% purity) were procured from Sigma–Aldrich Corporation (St. Louis, MO, USA) and used directly without further purification. Fluorescence studies Fluorescence spectroscopy measurements were conducted using a Hitachi F7000 (Hitachi Ltd., Tokyo, Japan) and a Perkin Elmer LS 55 fluorescence spectrometer equipped with a Peltier temperature controller (Perkin Elmer, Inc., USA). All samples were prepared in citrate-phosphate (CP) buffer (pH 7.12, 10 mM Na⁺), made with deionized and triple-distilled water filtered through 0.45 μm Millipore membranes (Millipore India Pvt. Ltd., Bangalore, India) to remove particulates. Protein concentrations were determined using molar extinction coefficients of 1.79 mM⁻¹·cm⁻¹ at 405 nm for human methemoglobin (HB) and 35,700 M⁻¹·cm⁻¹ at 280 nm for human serum albumin (HSA). Fluorescence quenching of HSA and HB was monitored by exciting at 295 nm, with excitation and emission slit widths set to 5 nm, targeting the intrinsic tryptophan (Trp) fluorophores. HB exhibited an emission peak at 327 nm upon excitation at 295 nm, indicating the β-Trp37 residue is buried within a hydrophobic environment. Circular dichroism (CD) spectra CD spectra were recorded at 25 °C using a PC-controlled Jasco J815 spectropolarimeter (JASCO International Co. Ltd., Tokyo, Japan) equipped with a Peltier-controlled cell holder and temperature controller (PFD 425 L/15). Measurements were performed in rectangular quartz cuvettes with a 0.1 cm path length. Each spectrum represents the average of four successive scans collected at a scan rate of 100 nm/min, with a bandwidth of 1.0 nm and sensitivity set to 200 mdeg. Baseline correction and spectral smoothing were applied within permissible limits using the instrument’s built-in software. Fixed concentrations of HSA and HB (1 µM) were titrated with increasing concentrations of Hep-C-dots. Molar ellipticity was reported as mean residue molar ellipticity [θ], expressed in degrees·cm²·dmol⁻¹. Cell culture A549 human lung adenocarcinoma cell line, a widely used model for human lung cancer research, was obtained from the National Centre for Cell Science (NCCS), Pune, India. They were cultured in MEM medium supplemented with 10% fetal calf serum (FCS) and 2% antibiotic solution containing 100 units/mL penicillin and 100 µg/mL streptomycin. These cells are relevant for studying nanoparticle interactions due to their origin from the respiratory system and expression of key cancer-related proteins. Cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂ to ensure optimal growth conditions. MTT assay Cells were grown in 60 mm culture plates until reaching 80–90% confluency. Subsequently, 100 µL of cell suspension, containing approximately 3,000 cells, was seeded into each well of a 96-well plate. The cells were then treated with varying concentrations (50 to 250 µg/mL) of Hep-C-dots and bare C-dots and incubated for 24 h. Following treatment, the medium was carefully removed, and 10 µL of 5 mg/mL MTT solution was added to each well. After a 3-hour incubation with the MTT reagent, 50 µL of isopropanol was added to dissolve the resulting formazan crystals. The absorbance was measured at 620 nm using a BMG Labtech UV spectrophotometer (Dutta et al., 2024). All the experiments were done in triplicate and the cytotoxicity was calculated by using the Eq. 1: Fluorescence microscopy A549 lung cancer cells were seeded onto sterile coverslips placed in 35 mm culture plates. After allowing the cells to adhere, they were treated with Hep-C-dots and bare C-dots at their respective IC₅₀ concentrations of 176.21 µg/mL and 200.4 µg/mL, followed by incubation for 24 h. The next day, the cells were washed twice with PBS, and the coverslips were mounted using 20% glycerol solution. Fluorescence imaging was performed using a Magnus MLX Plus microscope equipped with UV excitation (385 nm Epi-LED) and emission filters (300–400 nm range), and images were captured with the integrated overhead camera. Hemolytic assay The hemocompatibility of Hep-C-dots was evaluated using a hemolytic assay following the method described by Zhao et al.32 Fresh bovine red blood cells (RBCs) were collected in EDTA tubes and centrifuged at 1600 rpm for 5 min. The RBCs were washed four times with sterile PBS to remove plasma and white blood cells. Then, 0.2 mL of packed RBCs was diluted to 4 mL with PBS to prepare a 5% hematocrit suspension. This diluted RBC suspension was mixed with Hep-C-dots at concentrations of 200 and 400 µg/mL. Percent hemolysis was calculated using Eq. 2: (Eq. 2) where AS is the absorbance of the sample, AN is the absorbance of the negative control, and AP is the absorbance of the positive control. RBCs mixed with 0.8 mL PBS and 0.8 mL double distilled water served as the negative and positive controls, respectively.33. Results and discussion Synthesis and characterization of carbon dots In this work, heparin-capped carbon dots (Hep-C-dots) with uniform morphology and ultra-small size were synthesized via the dehydration of D-glucose using concentrated sulfuric acid (Fig. 1). Schematic representation of the synthesis of heparin-capped carbon dots (Hep-C-dots) from D-glucose. The formation of C-dots and Hep-C-dots was initially confirmed by analyzing the UV–visible spectra. UV-vis absorption peaks were observed at 281 nm for C-dots (Figure S1) and 221 nm and 280 nm for Hep-C-dots (Fig. 2a). No red or blue shifts were detected between the absorbance spectra of concentrated and diluted samples, indicating the absence of aggregation or dissociation upon dilution. Steady-state fluorescence measurements were performed to characterize the emission efficiency of the C-dots. The fluorescence emission spectra of C-dots and Hep-C-dots were collected in water. As can be seen in Figure S2, the emission intensity is dependent on the excitation wavelength, and the emission peaks are shifted to higher wavelengths with the increase of the excitation wavelength. The quantum yields of bare C-dots and Hep-C-dots are calculated and found to be about 7% and 9% respectively. The results are good agreement with the sugar derived C-dots reported in the literature.34,35 The size distributions of C-dots and Hep-C-dots were examined by transmission electron microscopy (TEM). The TEM micrographs (Fig. 2b for Hep-C-dots and Figure S3a for C-dots) showed monodisperse, nearly spherical particles with an average diameter of 2.5 ± 0.5 nm, as confirmed by the particle size distribution histogram (Fig. 2c). The particle size of the bare C-dots was determined to be 2.62 ± 0.71 nm (Figure S3b). X-ray diffraction (XRD) analysis was conducted to examine the crystalline structure of the synthesized C-dots. Figure 2d displays the X-ray diffraction (XRD) pattern of the synthesized Hep-C-dots over a 10–80° 2θ range. The XRD profile exhibits a broad peak centered at 25.04°, close to the graphite (002) diffraction peak at 26.1°,36 indicating an amorphous structure with a graphitic-like arrangement of carbon atoms. (a) UV-vis absorption spectrum of Hep-C-dots, showing characteristic peaks at 221 nm and 280 nm in aqueous solution. (b) Transmission electron microscopy (TEM) image of Hep-C-dots. (c) Particle size distribution histogram. (d) X-ray diffraction (XRD) pattern of Hep-C-dots, indicating their crystalline structure. Fourier-transform infrared (FTIR) spectroscopy was investigated to identify the surface functional groups and to confirm the chemical environment of the synthesized C-dots. FTIR spectra of both bare C-dots and Hep-C-dots were recorded and are presented in Fig. 3. The FTIR spectrum of bare C-dots exhibited a broad absorption band centered at 3412 cm⁻¹, attributed to O–H stretching vibrations, along with a peak at 1617 cm⁻¹ corresponding to C = O stretching vibrations. The band at 1423 cm⁻¹ was assigned to the bending vibrations of –OH groups from carboxylic acids.37 A peak at 1224 cm⁻¹ was observed, attributed to C–O–C stretching vibrations, characteristic of the pyran rings commonly found in flavonoid compounds.38 Previous studies on C-dot synthesis from D-glucose have reported the initial conversion of D-glucose to 5-hydroxymethyl furfural (5-HMF) derivatives, which subsequently undergo dehydrocondensation to form carbonaceous materials containing pyran ring structures.39 The absorption at 1001 cm⁻¹ was assigned to C–OH stretching vibrations present in the C-dots. The FTIR spectrum of Hep-C-dots confirmed successful functionalization with heparin. Key absorption bands included O–H stretching at 3369 cm⁻¹, sp³ C–H stretching at 2903 cm⁻¹, C = O stretching at 1729 cm⁻¹, and C = C stretching at 1644 cm⁻¹. The bands at 1567 cm⁻¹ and 1376 cm⁻¹ were attributed to the asymmetric and symmetric stretching vibrations of the carboxylate anion, respectively.40 Additionally, the presence of N–H bending at 1407 cm⁻¹, along with symmetrical (1235 cm⁻¹) and asymmetrical (1040 cm⁻¹) S = O stretching vibrations from NH–SO₃⁻ and CH₂–SO₃⁻ groups, respectively, confirmed the successful heparin capping of the C-dots.41. FTIR spectra of bare carbon dots (blue line) and heparin-capped carbon dots (Hep-C-dots, red line), highlighting the differences in surface functional groups after heparin functionalization. Zeta potential measurements were performed to assess the surface charge and predict the colloidal stability of the C-dots following surface functionalization. The zeta potential values of bare carbon dots, heparin, and heparin-capped carbon dots (Hep-C-dots) are presented in Table 1. The data reveals a marked increase in the negative surface charge of Hep-C-dots compared to the bare carbon dots. This significant enhancement in negative zeta potential is attributed to the presence of sulfate and carboxylate groups from the heparin coating on the carbon dot surface. A higher negative zeta potential typically correlates with increased electrostatic repulsion between particles, which helps prevent aggregation and improves the colloidal stability of the nanomaterial in aqueous suspension. Therefore, the observed rise in negative zeta potential confirms that heparin functionalization effectively stabilizes the carbon dots, making them more suitable for biological and biomedical applications where long-term dispersion and stability are critical. Table 1Zeta potential values of carbon dots, heparin and Hep-C-dots.SampleZeta potential (mV)Carbon dots-17.6Heparin-19.2Hep-C-dots-36.8 Zeta potential values of carbon dots, heparin and Hep-C-dots. X-ray photoelectron spectroscopy (XPS) was conducted to measure the elemental composition and determine the chemical environment of the surface atoms before and after functionalization. As shown in Fig. S4A, the XPS full scan spectra of C-dots indicates that there are four clear peaks around 165 eV, 281 eV, 396 eV, and 529 eV ascribed to sulfur (8.34%), carbon (44.63%), nitrogen (1.27%), and oxygen (45.76%), respectively. The high-resolution spectrum of C1s (Fig. S4B) displayed two main peaks at 285.2 and 287.7 which could be attributed to C–C and C–O, respectively. The high-resolution spectrum of O1s (Fig. S4C) showed two characteristic oxygen states, C = O (531.2 eV) and C–O (532.9 eV), which was consistent with the spectrum of C1s. After the surface functionalization of C-dots with heparin, percent composition and peak positions were slightly changed (Fig. S4D). Increasing oxygen (60.78%) and sulfur (14.39%) composition indicates the successful surface functionalization of C-dots with heparin. According to the high-resolution spectrum of C1s shown in Fig. 4SE, three peaks at 284.2 eV, 285.2 eV, and 286.8 eV can be attributed to the C–C, C–N and C–O, respectively. The high-resolution spectrum of O1s in Fig. 4SF, showed two characteristic oxygen states, C = O (530.8 eV) and C–O (532.5 eV), which was consistent with the spectrum of C1s spectrum of Hep-C-dots. Protein binding analysis Fluorescence analysis The effect of Hep-C-dots on the intrinsic fluorescence intensity of human serum albumin (HSA) and human methemoglobin (HB) is depicted in Fig. 4a and b, respectively. In Fig. 4a, curves 1 to 8 correspond to Hep-C-dots concentrations of 0, 5, 10, 15, 20, 25, 30, and 35 nM, while in Fig. 4b, curves 1 to 12 represent increasing Hep-C-dots concentrations ranging from 0 to 55 nM in increments of 5 nM. A clear trend of decreasing fluorescence intensity was observed for both HSA and HB with increasing concentrations of Hep-C-dots, indicating effective quenching of the proteins’ intrinsic fluorescence by the carbon dots. This progressive quenching strongly suggests that Hep-C-dots interact with both HSA and HB, likely through binding events that affect the microenvironment of the proteins’ intrinsic fluorophores, primarily tryptophan residues. Fluorescence quenching in such systems can arise from either dynamic (collisional) or static (complex formation) mechanisms. To distinguish between these possibilities and quantify the quenching effect, the Stern-Volmer Eq. (3) was employed for data analysis: Steady state fluorescence emission spectra of (a) human serum albumin (HSA) treated with 0, 5, 10, 15, 20, 25, 30 and 35 nM of Hep-C-dots denoted by curves (1–8) and (b) human methemoglobin (HB) treated with 0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50 and 55 nM of Hep-C-dots denoted by curves (1–12), (c) and (d) shows the unmodified Stern−Volmer plot for HSA-Hep-C-dots and HB-Hep-C-dots, respectively showing strong quenching behavior consistent with static binding interactions. where F0 and F represent the steady-state fluorescence intensities of the protein in the absence and presence of the quencher (Hep-C-dots), respectively; KSV is the Stern-Volmer quenching constant; and [Q] is the concentration of the quencher. Equation 1 was applied to determine KSV by linear regression of a plot of F0/F against [Q]. The calculated KSV, Kq and R2 values are presented in Table 2. Table 2Binding constant derived from the Stern-Volmer method at 25 °C.SystemKsvKq R 2 HSA2.61 ± 0.5 × 107 M− 13.78 ± 0.18 × 1015 M− 1 s− 10.99123HB1.83 ± 0.4 × 107 M− 17.09 ± 0.08 × 1015 M− 1 s− 10.98934 Binding constant derived from the Stern-Volmer method at 25 °C. Figure 4c and d present the unmodified Stern–Volmer plots for HSA–C-dots and HB–C-dots. From the slope of Eq. (1), the Stern–Volmer quenching constants (KSV) were determined to be 2.61 ± 0.5 × 10⁷ M⁻¹ (average of three measurements) for HSA and 1.83 ± 0.4 × 10⁷ M⁻¹ for HB, obtained through linear regression analysis. These results indicate a strong quenching ability of Hep-C-dots toward both HSA and HB. From Eq. (1), the bimolecular quenching constant (Kq) can be calculated using the relation KSV = kqτ0. By assuming the lifetime (τ0) of approximately 6.89 × 10− 8 s for HSA and 2.58 × 10− 9 s for HB, the calculated Kq values were 3.78 ± 0.18 × 1015 M− 1 s− 1 and 7.09 ± 0.08 × 1015 M− 1 s− 1, respectively. Notably, these Kq values exceed the maximum diffusion-controlled quenching rate constant (1 × 1010 M− 1 s− 1), indicating that the quenching is not governed by simple collisional processes but rather by the formation of stable complexes between Hep-C-dots and the proteins. This strongly supports static quenching as the dominant mechanism, suggesting that Hep-C-dots bind specifically to HSA and HB, causing conformational changes or microenvironmental alterations that result in fluorescence quenching. CD spectroscopy Changes in the secondary and tertiary structures of proteins can be sensitively detected using circular dichroism (CD) spectroscopy, which provides insight into protein folding and conformational stability. The far-UV CD spectrum of native human serum albumin (HSA) displayed two prominent negative minima at 208 nm and 222 nm (Fig. 5a), characteristic signatures of α-helical structures. This spectral pattern aligns well with previously reported findings and confirms the well-folded, native conformation of HSA under the experimental conditions (Serro et al., 2004; Norde & Giacomelli, 2000). Secondary structure analysis via the Jasco software estimated that native HSA is composed of approximately 53.6% α-helix, 27.1% β-sheet (comprising both parallel and antiparallel strands), and 19.3% random coil regions, reflecting its typical globular protein architecture. Upon titration with increasing concentrations of Hep-C-dots, a progressive reduction in the intensity of the CD signals at 208 nm and 222 nm was observed. This decrease indicates a loss or partial unfolding of α-helical content, which suggests that the interaction with Hep-C-dots induces conformational changes in HSA’s secondary structure. At the highest tested concentration (300 nM Hep-C-dots), the α-helix content decreased by approximately 12%, while β-sheet and random coil contents showed corresponding increases. These alterations imply a shift toward a less ordered secondary structure, possibly due to loosening or partial destabilization of the helices. Such structural perturbations support the hypothesis that Hep-C-dots directly bind to HSA, affecting its conformational dynamics. This binding may cause local unfolding or rearrangement of protein regions, leading to increased exposure of β-sheet and random coil motifs. Importantly, these secondary structural changes are relatively moderate, indicating that while Hep-C-dots interact strongly with HSA, they do not cause extensive denaturation or loss of overall protein integrity. From a biological perspective, these findings suggest that Hep-C-dots can modulate protein structure in a way that may influence HSA’s physiological functions, such as ligand binding, transport capacity, and stability in circulation. Understanding these subtle conformational changes is crucial for evaluating the biocompatibility and safety of Hep-C-dots, especially for potential biomedical applications where protein interactions are inevitable. Further insights into the interaction between Hep-C-dots and human methemoglobin (HB) were gained from circular dichroism (CD) spectroscopy, which monitors changes in the protein’s secondary structure. As illustrated in Fig. 5b, the far-UV CD spectrum of native HB displayed two characteristic negative bands at 208 and 222 nm, typical of its α-helical conformation. The 208 nm band corresponds to the π→π* transition of the α-helix, while the 222 nm band is attributed to the n→π* transition associated with both α-helix and random coil structures, arising primarily from peptide bond transitions. Upon incubation with 300 nM Hep-C-dots, HB exhibited a decrease in α-helical content by approximately 12.5%, reflecting a subtle perturbation in its secondary structure. This moderate reduction suggests a slight unfolding or rearrangement in the protein’s helical regions upon binding. These CD results are consistent with the fluorescence studies, indicating that Hep-C-dots induce only minor conformational changes in HB, particularly around the heme-containing subunits. This limited structural alteration implies that the functional integrity of HB, especially in the heme environment, remains largely preserved despite Hep-C-dot interaction. Table 3 summarizes the quantitative changes in secondary structure content at various Hep-C-dot concentrations, providing a detailed view of the dose-dependent conformational effects. Circular dichroism (CD) Spectra of (a) HSA and (b) HB on addition of increasing concentrations of Hep-C-dots. Table 3Analysis of percentage of helix in HSA and HB at 25 °C in presence of varied concentrations of Hep-C-dots.SystemCNP/Pα-helixβ-sheet% Random coilHSA053.627.119.30.1051.427.720.90.2049.528.222.30.3047.229.723.1HB048.834.616.60.1046.535.917.60.2044.637.318.10.3042.738.418.9 Analysis of percentage of helix in HSA and HB at 25 °C in presence of varied concentrations of Hep-C-dots. Cytotoxicity Study The cytotoxicity of Hep-C-dots and bare C-dots against A549 lung cancer cells was evaluated using the MTT assay, a widely employed colorimetric method for assessing cell viability. This assay is based on the reduction of MTT dye by mitochondrial oxidoreductase enzymes in metabolically active live cells, resulting in the formation of insoluble purple formazan crystals (Liu and Schubert, 2002). Our results demonstrated that both Hep-C-dots and bare C-dots exhibit dose-dependent cytotoxic effects on A549 cells. The half-maximal inhibitory concentration (IC₅₀) values were determined by straight line equations (Y = 0.2224X + 10.81, R2 = 0.9985 & Y = 0.2072X + 8.4754, R2 = 0.9983 for Hep-C-dots and bare C-dots respectively) and was 176.21 µg/mL for Hep-C-dots and 200.4 µg/mL for bare C-dots, as shown in Fig. 6. Notably, the modest increase in cytotoxic potency of C-dots against lung cancer cells following heparin functionalization appears to be independent of particle size, as both bare and functionalized dots remain within a similar size range. Instead, the enhanced efficacy is likely driven by surface-mediated interactions, with the heparin coating facilitating improved cellular uptake and/or stronger interactions with cellular components. MTT cytotoxicity assay of Hep-C-dots and bare C-dots on A549 lung cancer cells. The bar diagram shows dose-dependent cytotoxic effects, with IC₅₀ values of 176.21 µg/mL and 200.4 µg/mL for Hep-C-dots and bare C-dots, respectively, with 5% error bars, indicating slightly higher toxicity for Hep-C-dots. Fluorescence microscopy and cell morphology study Given the observed cytotoxicity of both Hep-C-dots and bare C-dots toward A549 lung carcinoma cells, further investigation was conducted to examine their impact on cellular morphology using phase contrast microscopy. Morphological alterations serve as vital indicators of the type and extent of cell death, including apoptosis and necrosis. Upon treatment with Hep-C-dots at their IC₅₀ concentration (176.21 µg/mL), distinct morphological features characteristic of apoptosis was observed. These included noticeable cell shrinkage, loss of membrane integrity, the presence of apoptotic bodies, and a marked reduction in cell adherence to the culture plate surface (Fig. 7a). Such morphological changes are consistent with apoptotic pathways as previously described in the literature.42 In contrast, cells treated with bare C-dots at 200.4 µg/mL exhibited features more aligned with necrotic cell death. These included cytoplasmic vacuolization, cellular swelling, and pronounced loss of adherence. The presence of vacuoles and increased cell size are typical hallmarks of necrosis and suggest a different mode of cell death induced by non-functionalized C-dots. Fluorescence imaging further supported the cellular internalization of Hep-C-dots. As shown in Fig. 7b, Hep-C-dots demonstrated significant fluorescence emission within the cytoplasmic region of A549 cells, indicating their successful uptake and intracellular localization. The intrinsic fluorescence of Hep-C-dots facilitated their tracking inside the cells, affirming their potential utility as both therapeutic and diagnostic (theranostic) agents in cancer treatment. Microscopic observation of apoptosis in A549 lung cancer cells following treatment with Hep-C-dots and bare C-dots. (a) Bright-field images of A549 cells treated with Hep-C-dots at concentrations of 176.21 µg/mL and 200.4 µg/mL, as well as with bare C-dots, showing morphological features indicative of apoptosis. Scale bar: 50 μm. (b) Fluorescence microscopy images of A549 cells after treatment with Hep-C-dots, captured at 10× and 40× magnification. Apoptotic features such as nuclear condensation and membrane blebbing are visible. Scale bars: 50 μm (10×) and 25 μm (40×). Hemocompatibility assay For the safe in-vivo application of any therapeutic agent or nanoparticle, initial hemocompatibility assessment is essential to evaluate potential adverse interactions with blood components. Although mechanisms of cytotoxicity may differ across various cell types, a standard hemolysis assay provides a valuable first-line screening method to determine whether a material induces damage to red blood cells (RBCs) through membrane disruption or oxidative stress. In this study, the hemocompatibility of heparin-capped carbon dots (Hep-C-dots) was evaluated by quantifying hemolysis in bovine red blood cells. Hep-C-dots were suspended at a concentration of 200 µg/mL in phosphate-buffered saline (PBS) and incubated with a 5% hematocrit RBC suspension. Following incubation, the mixtures were centrifuged, and the supernatants were analyzed both visually and spectrophotometrically at 541 nm to detect the release of hemoglobin (Fig. 8). Minimal coloration in the supernatant and negligible absorbance at 541 nm confirmed the lack of significant RBC lysis. Quantitatively, Hep-C-dots induced only 0.002% hemolysis at the tested concentration. According to established biocompatibility criteria, materials inducing < 5% hemolysis are considered hemocompatible and safe for biomedical use.43 The observed value, which is well below this threshold, indicates excellent compatibility of Hep-C-dots with erythrocytes and supports their potential utility for intravenous applications without posing a risk of hemolytic toxicity. These findings demonstrate that the incorporation of heparin -a biocompatible, sulfated polysaccharide- on the carbon dot surface not only stabilizes the nanomaterials but also contributes to their non-hemolytic behavior, making Hep-C-dots suitable candidates for future biomedical and theranostic applications. Hemocompatibility assessment of Hep-C-dots using bovine red blood cells (RBCs). Bovine RBCs were incubated with varying concentrations of Hep-C-dots to evaluate hemolytic activity. PBS (0.8 mL) and double-distilled water (0.8 mL) were used as negative and positive controls, respectively. Hemolysis was assessed by measuring the absorbance of the supernatant after incubation, with increased absorbance indicating higher levels of RBC lysis. Conclusions In summary, this study demonstrates the successful synthesis of heparin-functionalized carbon dots (Hep-C-dots) via a green, bottom-up approach using D-glucose as the carbon source. The resulting nanodots were found to be monodispersed, ultrasmall (2.5 ± 0.5 nm), and highly water-soluble, owing to the surface modification with the negatively charged polysaccharide, heparin. Characterization through UV–Vis, FTIR, TEM, XRD, and zeta potential analyses confirmed their stable graphitic structure, functional group incorporation, and enhanced colloidal stability. Biological evaluations of Hep-C-dots revealed promising therapeutic potential. In vitro cytotoxicity assays against A549 lung carcinoma cells showed that Hep-C-dots exhibit a lower IC₅₀ value (176.21 µg/mL) compared to bare C-dots (200.4 µg/mL), indicating improved anticancer efficacy likely due to surface-mediated cellular interactions. Microscopy analysis further confirmed morphological changes consistent with apoptosis in Hep-C-dot-treated cells, whereas bare C-dots induced features resembling necrosis. Additionally, fluorescence microscopy confirmed cellular uptake and intracellular localization of Hep-C-dots, highlighting their potential as bioimaging and drug delivery agents. The biocompatibility of Hep-C-dots was affirmed by hemolysis assays, which showed negligible hemolytic activity (0.002%) at 200 µg/mL-well below the accepted 5% threshold—demonstrating excellent hemocompatibility for biomedical use. Protein-binding studies using fluorescence quenching and circular dichroism spectroscopy revealed that Hep-C-dots interact specifically with key plasma proteins, human serum albumin (HSA) and human methemoglobin (HB), without inducing major conformational disruptions. The static nature of the fluorescence quenching and moderate structural changes observed in CD spectra suggest a favourable interaction mechanism that preserves protein functionality. Overall, these findings underscore the potential of Hep-C-dots as a multifunctional nanoplatform with applications in targeted cancer therapy, bioimaging, and drug delivery. Their excellent biocompatibility, stability, and specific biomolecular interactions make them strong candidates for further preclinical development and therapeutic exploitation. Future studies will focus on mechanistic assays (Annexin V, caspase activity) and quantitative cellular uptake to better understand the pathways of cell death and internalization of Hep-C-dots. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements M.D.Y. thanks to Necmettin Erbakan University BITAM─Science and Technology Research and Application Center for the use of the facilities. Author contributions Ipsita Kumar Sen, Maidul Hossain, Debesh Chandra Bhattacharya, Anoop Kumar, and Ahmet Kati performed the experiments. Amiya Kumar Panda, M. Deniz Yilmaz, and Amit Kumar Mandal wrote the manuscript. All authors reviewed the manuscript. Funding A.K.M would like to acknowledge DST-SERB India (EEQ/2021/000058) for financial support. Data availability All experimental data involved in this study are included in this article. Correspondence and requests for materials should be addressed to Ipsita Kumar Sen and Amit Kumar Mandal. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Ipsita Kumar Sen, Email: senipsitakumar007@gmail.com. M. Deniz Yilmaz, Email: deniz.yilmaz@erbakan.edu.tr. Amit Kumar Mandal, Email: amitmandal08@gmail.com. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All experimental data involved in this study are included in this article. Correspondence and requests for materials should be addressed to Ipsita Kumar Sen and Amit Kumar Mandal.